Related Experiment Video
Updated: May 26, 2026
08:47
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Eukaryotic initiation factor 4F: a vulnerability of tumor cells
1Department of Biochemistry, McGill University, Montreal, QC H3G 1Y6, Canada.
Future Medicinal Chemistry
|December 16, 2011
Summary
Targeting eIF4F, a key protein complex in cancer, offers a therapeutic opportunity. Inhibiting eIF4E, a component of eIF4F, shows promise for cancer treatment by disrupting tumor growth.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Protein synthesis is crucial for eukaryotic cell function and tightly regulated.
- Deregulation of protein synthesis is a hallmark of many cancers.
- Translational control, particularly initiation, is a key regulatory step involving eukaryotic initiation factors (eIFs).
Purpose of the Study:
- To review approaches for targeting the eIF4F complex in cancer therapy.
- To highlight the role of eIF4E in tumor initiation and progression.
- To explore therapeutic vulnerabilities associated with eIF4F activity.
Main Methods:
- Review of existing literature on eIF4F complex and its components.
- Analysis of the role of eIF4E in cancer cell transformation and animal models.
- Discussion of therapeutic strategies targeting eIF4F activity.
Main Results:
- Overexpression of eIF4E cooperates with oncogenes to accelerate cell transformation.
- Elevated levels of eIF4E are observed in many human cancers.
- The eIF4F complex, particularly eIF4E, represents a vulnerability in cancer cells.
Conclusions:
- Targeting eIF4F activity presents a promising therapeutic intervention for cancer.
- Inhibiting eIF4E offers a potential strategy to combat cancer progression.
- Understanding eIF4F regulation is key to developing novel cancer treatments.
Related Concept Videos
02:33Initiation of Translation
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...